Nautilus Biotechnology (NASDAQ:NAUT) Price Target Raised to $4.00 at Guggenheim

Nautilus Biotechnology (NASDAQ:NAUT) had its target price hoisted by investment analysts at Guggenheim from $2.50 to $4.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Guggenheim’s price target points to a potential upside of 65.63% from the company’s current price.

NAUT has been the subject of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. Wall Street Zen raised Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research report on Tuesday, November 18th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $4.00.

Nautilus Biotechnology Stock Performance

Shares of NAUT traded down $0.01 on Friday, reaching $2.42. The stock had a trading volume of 27,032 shares, compared to its average volume of 217,940. Nautilus Biotechnology has a 12-month low of $0.62 and a 12-month high of $3.08. The firm has a market capitalization of $305.04 million, a price-to-earnings ratio of -4.84 and a beta of 1.49. The company has a 50-day simple moving average of $2.15 and a 200-day simple moving average of $1.56.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.03. On average, analysts expect that Nautilus Biotechnology will post -0.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE lifted its stake in shares of Nautilus Biotechnology by 37.1% during the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock valued at $83,000 after buying an additional 13,363 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in shares of Nautilus Biotechnology in the first quarter worth about $194,000. Acadian Asset Management LLC lifted its position in shares of Nautilus Biotechnology by 468.3% in the first quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after buying an additional 50,871 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Nautilus Biotechnology in the second quarter worth about $163,000. Finally, XTX Topco Ltd grew its holdings in Nautilus Biotechnology by 86.2% during the 2nd quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock valued at $48,000 after buying an additional 30,641 shares in the last quarter. Institutional investors own 50.71% of the company’s stock.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.